Impact of molecular subtypes on prognosis of postoperative patients with invasive breast cancer
10.3760/cma.j.cn113855-20220109-00014
- VernacularTitle:分子分型对可手术浸润性乳腺癌预后的影响
- Author:
Dechuang JIAO
1
;
Jiujun ZHU
;
Xuhui GUO
;
Yue YANG
;
Hao DAI
;
Yajie ZHAO
;
Lianfang LI
;
Chengzheng WANG
;
Zhenduo LU
;
Xiuchun CHEN
;
Zhenzhen LIU
Author Information
1. 郑州大学附属肿瘤医院（河南省肿瘤医院）乳腺科,郑州 450008
- Keywords:
Breast neoplasms;
Prognosis;
Molecular subtype
- From:
Chinese Journal of General Surgery
2022;37(8):573-578
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the prognostic value of molecular subtypes in patients with resected invasive breast cancer.Methods:Between 2015 and 2018 7 869 patients with invasive breast cancer after undergoing surgery were included in this analysis. Breast cancer was classified into four subtypes according to the status of hormone receptor (HR) and HER2: HR+/HER2-, HR+/HER2+, HR-/HER2+, and HR-/HER2-. Kaplan-Meier curves and COX regression were used to compare disease-free survival (DFS) and overall survival (OS) among different subtypes.Results:The 5-year DFS and OS were 86.30% and 94.29%, respectively. Proportions of HR+/HER2-、HR+/HER2+、HR-/HER2+ and HR-/HER2- were 52.9%、17.5%、14.1%和15.5%, respectively. The 5-year DFS of HR+/HER2- subtype (88.12%) was higher than HR+/HER2+ (84.67%, P=0.026), HR-/HER2+ (84.19%, P<0.001) and HR-/HER2- (83.70%, P<0.001). The 5-year OS of HR+/HER2- (95.38%) was not different from HR+/HER2+ (95.17%, P=0.187), while it was higher than that of HR-/HER2+ (92.26%, P<0.001) and HR-/HER2- (91.69%, P<0.001). Subtype was still a significant factor regarding DFS and OS in multivariable analyses adjusting for age, sex, stage, Ki67, types and time of surgery. The DFS ( P=0.257) and OS ( P=0.511) was not different between HR-/HER2+与HR+/HER2- subtypes, while HR-/HER2+ and HR-/HER2- patients had worse DFS ( P<0.05) and OS ( P<0.05) than that with HR+/HER2-. Conclusions:Molecular subtype is a significant independent prognostic factor for DFS and OS in operable invasive breast cancer. HR+ subtypes have better prognosis compared with HR- subtypes. The DFS and OS were not different between HR+/HER2- and HR+/HER2+, or between HR-/HER2+ and HR-/HER2-.
